Cantor Fitzgerald Expects Increased Earnings for Prothena

Prothena Co. plc (NASDAQ:PRTA) – Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for shares of Prothena in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings of ($3.59) per share for the year, up from their previous forecast of ($3.61). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.20). The firm had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The business’s revenue for the quarter was up 5500.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.34) EPS.

A number of other analysts have also recently weighed in on the stock. Oppenheimer raised their price objective on shares of Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a report on Friday, February 7th. HC Wainwright cut their price target on shares of Prothena from $48.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Royal Bank of Canada decreased their price objective on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a research note on Friday, February 21st. JMP Securities dropped their price objective on Prothena from $80.00 to $78.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. Finally, StockNews.com raised Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.71.

Prothena Stock Performance

Shares of NASDAQ PRTA opened at $7.59 on Wednesday. The stock’s 50-day simple moving average is $10.80 and its 200-day simple moving average is $13.47. The firm has a market capitalization of $408.55 million, a PE ratio of -3.30 and a beta of 0.11. Prothena has a fifty-two week low of $6.92 and a fifty-two week high of $25.42.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PRTA. Wellington Management Group LLP grew its holdings in shares of Prothena by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company’s stock worth $71,063,000 after buying an additional 952,088 shares during the last quarter. Boxer Capital Management LLC acquired a new position in Prothena in the 4th quarter valued at $9,556,000. Federated Hermes Inc. raised its position in Prothena by 84.3% during the 4th quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company’s stock worth $10,335,000 after buying an additional 341,274 shares during the last quarter. Finepoint Capital LP lifted its stake in shares of Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company’s stock worth $9,100,000 after acquiring an additional 223,600 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Prothena by 93.7% in the fourth quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company’s stock valued at $5,365,000 after acquiring an additional 187,364 shares in the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.